The DOI matches its Crossref record.
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
Abstract
Learning Objectives: Evaluate the evidence of improved overall survival with the use of sorafenib for the treatment of unresectable hepatocellular carcinoma. Recognize the potential for drug interactions for sorafenib with concurrent use of drugs that can induce or inhibit CYP3A4. Recognize side effects of sorafenib therapy including elevated blood pressure, diarrhea, fatigue, skin rash/ desquamation, hand–foot skin reaction, alopecia, and nausea, and counsel your patients about side effect management. This article is available for continuing medical education credit at CME.TheOncologist.com.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Challenges in liver cancer and possible treatment approaches
Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188314 · Cited by 1,481
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
Chen, X., & Calvisi, D. F. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.002 · Cited by 434
Metadata
- Authors
- Kane, R. C., Farrell, A. T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R., & Pazdur, R.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 14
- Issue
- 1
- Pages
- 95-100
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2151214205
- Cited by
- 221
- References
- 0
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1634/theoncologist.2008-0185
- The paper
- Kane, R. C., Farrell, A. T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R., & Pazdur, R. (2009). Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma. The Oncologist. https://doi.org/10.1634/theoncologist.2008-0185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.